<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7505219/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>Influenza antiviral drugs currently available and under clinical trial [ 
   <a ref-type="bibr" rid="CR98">98</a>, 
   <a ref-type="bibr" rid="CR99">99</a>] 
  </p>
 </caption>
 <thead>
  <tr>
   <th align="left" colspan="1" rowspan="1" id="0-0-.">Drug</th>
   <th align="left" colspan="1" rowspan="1" id="0-1-.">Generic name</th>
   <th align="left" colspan="1" rowspan="1" id="0-2-.">Availability for use</th>
   <th align="left" colspan="1" rowspan="1" id="0-3-.">Effective against</th>
   <th align="left" colspan="1" rowspan="1" id="0-4-.">Specific Target</th>
   <th align="left" colspan="1" rowspan="1" id="0-5-.">Status</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left">Oseltamivir</td>
   <td align="left">Tamiflu®</td>
   <td align="left">Oral</td>
   <td align="left">IAV and IBV</td>
   <td align="left" rowspan="3">Blocks NA protein and inhibit the release of virions after budding from the host cell</td>
   <td align="left" rowspan="3">Approved</td>
  </tr>
  <tr>
   <td align="left">Zanamivir</td>
   <td align="left">Relenza®</td>
   <td align="left">Inhalation</td>
   <td align="left">IAV and IBV</td>
  </tr>
  <tr>
   <td align="left">Peramivir</td>
   <td align="left">Rapivab®</td>
   <td align="left">Intravenous</td>
   <td align="left">IAV and IBV</td>
  </tr>
  <tr>
   <td align="left">Amantadine</td>
   <td align="left">Symmetrel</td>
   <td align="left" rowspan="2">Oral</td>
   <td align="left" rowspan="2">IAV</td>
   <td align="left" rowspan="2">Inhibits viral replication by blocking M2 membrane protein</td>
   <td align="left" rowspan="2">Approved but currently not in use due to high resistance to IAV</td>
  </tr>
  <tr>
   <td align="left">Remantadine</td>
   <td align="left">Flumadine</td>
  </tr>
  <tr>
   <td align="left">Baloxavir marboxil</td>
   <td align="left">Xofluza®</td>
   <td align="left">Oral</td>
   <td align="left">IAV and IBV</td>
   <td align="left">Inhibit the cap-dependent endonuclease protein</td>
   <td align="left">Approved</td>
  </tr>
  <tr>
   <td align="left">Nitazoxanide</td>
   <td align="left">Nizonide</td>
   <td align="left">Oral</td>
   <td align="left">IAV (H1, H3, H5, H7) and IBV</td>
   <td align="left">Inhibits replication of virus by vitiate the trafficking of the HA protein from the endoplasmic reticulum to the Golgi complex</td>
   <td align="left">Under clinical trial phase III</td>
  </tr>
  <tr>
   <td align="left">DAS181</td>
   <td align="left">Fludase®</td>
   <td align="left">Oral/inhalation</td>
   <td align="left">(H1N1)pdm09, H3N2, H7N9, H5N1 and IBV</td>
   <td align="left">Remove silaic acid receptor from host and block the binding and entry of virus to the host cell</td>
   <td align="left">Phase I,II</td>
  </tr>
  <tr>
   <td align="left">T705</td>
   <td align="left">favipiravir</td>
   <td align="left">Oral</td>
   <td align="left">IAV, IBV and ICV</td>
   <td align="left">Inhibitor of RNA dependent RNA polymerase</td>
   <td align="left">Phase II, III</td>
  </tr>
 </tbody>
</table>
